Ignite Creation Date:
2025-12-25 @ 4:37 AM
Ignite Modification Date:
2025-12-26 @ 3:39 AM
Study NCT ID:
NCT06090318
Status:
WITHDRAWN
Last Update Posted:
2023-10-19
First Post:
2022-11-14
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
Sponsor:
Rain Oncology Inc
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-05-19
Start Date Type:
ACTUAL
Primary Completion Date:
2023-05-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-05-30
Completion Date Type:
ACTUAL
First Submit Date:
2022-11-14
First Submit QC Date:
None
Study First Post Date:
2023-10-19
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-10-16
Last Update Post Date:
2023-10-19
Last Update Post Date Type:
ACTUAL